



REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,
Madhapur, Hyderabad - 500 081, Telangana, INDIA.
Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com
CIN: L24110TG1991PLC012471

Dated: September 02, 2021

To,
National Stock Exchange of India Limited
BSE Limited
Symbol: NSE: GRANULES; BSE: 532482

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,

Please be informed that, the Company has received licence from Defence Research & Development Organisation (DRDO), Ministry of Defence, Government of India, to manufacture and market of 2- Deoxy-D-Glucose (2-DG). Developed by DRDO, 2-DG has been granted permission by Drug Controller General of India (DCGI) for emergency use of this drug as adjunct therapy in moderate to severe Covid 19 patients.

2-DG works by accumulating in virus infected cells and prevent growth of the virus by stopping energy production and viral synthesis. This drug reduces a patient's average recovery time by two and half days and oxygen demand by up to 40 percent.


Granules is working closely with DRDO team to launch the product in India at the earliest.

This is for your information and dissemination to the members of the exchange.

Thanking You.
Yours sincerely,

For GRANULES INDIA LIMITED

G. Chaitanya



**CHAITANYA TUMMALA
(COMPANY SECRETARY &
COMPLIANCE OFFICER)**